1
|
Strother CA, Brewer-Jensen PD, Becker-Dreps S, Zepeda O, May S, Gonzalez F, Reyes Y, McElvany BD, Averill AM, Mallory ML, Montmayeur AM, Costantini VP, Vinjé J, Baric RS, Bucardo F, Lindesmith LC, Diehl SA. Infant antibody and B-cell responses following confirmed pediatric GII.17 norovirus infections functionally distinguish GII.17 genetic clusters. Front Immunol 2023; 14:1229724. [PMID: 37662930 PMCID: PMC10471973 DOI: 10.3389/fimmu.2023.1229724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Accepted: 07/25/2023] [Indexed: 09/05/2023] Open
Abstract
Genogroup II (GII) noroviruses are a major cause of diarrheal disease burden in children in both high- and low-income countries. GII.17 noroviruses are composed of distinct genetic clusters (I, II, IIIa, and IIIb) and have shown potential for replacing historically more prevalent GII.4 strains, but the serological basis for GII.17 antigenic diversity has not been studied in children. Utilizing samples from a birth cohort, we investigated antibody and B-cell responses to GII.17 cluster variants in confirmed GII.17 infections in young children as well as demonstrated that the distinct genetic clusters co-circulate. Polyclonal serum antibodies bound multiple clusters but showed cluster-specific blockade activity in a surrogate virus neutralization assay. Antibodies secreted by immortalized memory B cells (MBCs) from an infant GII.17 case were highly specific to GII.17 and exhibited blockade activity against this genotype. We isolated an MBC-derived GII.17-specific Immunoglobulin A (IgA) monoclonal antibody called NVA.1 that potently and selectively blocked GII.17 cluster IIIb and recognized an epitope targeted in serum from cluster IIIb-infected children. These data indicate that multiple antigenically distinct GII.17 variants co-circulate in young children, suggesting retention of cluster diversity alongside potential for immune escape given the existence of antibody-defined cluster-specific epitopes elicited during infection.
Collapse
Affiliation(s)
- Camilla A. Strother
- Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, VT, United States
- Cellular, Molecular, and Biomedical Sciences Graduate Program, University of Vermont, Burlington, VT, United States
- Translational Global Infectious Disease Research Center, Larner College of Medicine, University of Vermont, Burlington, VT, United States
| | - Paul D. Brewer-Jensen
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
| | - Sylvia Becker-Dreps
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
- Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
| | - Omar Zepeda
- Department of Microbiology and Parasitology, Faculty of Medical Sciences, National Autonomous University of Nicaragua, León, Nicaragua
| | - Samantha May
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
| | - Fredman Gonzalez
- Department of Microbiology and Parasitology, Faculty of Medical Sciences, National Autonomous University of Nicaragua, León, Nicaragua
| | - Yaoska Reyes
- Department of Microbiology and Parasitology, Faculty of Medical Sciences, National Autonomous University of Nicaragua, León, Nicaragua
| | - Benjamin D. McElvany
- Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, VT, United States
| | - April M. Averill
- Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, VT, United States
| | - Michael L. Mallory
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
| | - Anna M. Montmayeur
- National Calicivirus Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Verónica P. Costantini
- National Calicivirus Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Jan Vinjé
- National Calicivirus Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, United States
| | - Ralph S. Baric
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
| | - Filemon Bucardo
- Department of Microbiology and Parasitology, Faculty of Medical Sciences, National Autonomous University of Nicaragua, León, Nicaragua
| | - Lisa C. Lindesmith
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
| | - Sean A. Diehl
- Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, VT, United States
- Cellular, Molecular, and Biomedical Sciences Graduate Program, University of Vermont, Burlington, VT, United States
- Translational Global Infectious Disease Research Center, Larner College of Medicine, University of Vermont, Burlington, VT, United States
| |
Collapse
|
2
|
Weaver DT, McElvany BD, Gopalakrishnan V, Card KJ, Crozier D, Dhawan A, Dinh MN, Dolson E, Farrokhian N, Hitomi M, Ho E, Jagdish T, King ES, Cadnum JL, Donskey CJ, Krishnan N, Kuzmin G, Li J, Maltas J, Mo J, Pelesko J, Scarborough JA, Sedor G, Tian E, An GC, Diehl SA, Scott JG. UV decontamination of personal protective equipment with idle laboratory biosafety cabinets during the COVID-19 pandemic. PLoS One 2021; 16:e0241734. [PMID: 34310599 PMCID: PMC8312969 DOI: 10.1371/journal.pone.0241734] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Accepted: 06/19/2021] [Indexed: 11/22/2022] Open
Abstract
Personal protective equipment (PPE) is crucially important to the safety of both patients and medical personnel, particularly in the event of an infectious pandemic. As the incidence of Coronavirus Disease 2019 (COVID-19) increases exponentially in the United States and many parts of the world, healthcare provider demand for these necessities is currently outpacing supply. In the midst of the current pandemic, there has been a concerted effort to identify viable ways to conserve PPE, including decontamination after use. In this study, we outline a procedure by which PPE may be decontaminated using ultraviolet (UV) radiation in biosafety cabinets (BSCs), a common element of many academic, public health, and hospital laboratories. According to the literature, effective decontamination of N95 respirator masks or surgical masks requires UV-C doses of greater than 1 Jcm−2, which was achieved after 4.3 hours per side when placing the N95 at the bottom of the BSCs tested in this study. We then demonstrated complete inactivation of the human coronavirus NL63 on N95 mask material after 15 minutes of UV-C exposure at 61 cm (232 μWcm−2). Our results provide support to healthcare organizations looking for methods to extend their reserves of PPE.
Collapse
Affiliation(s)
- Davis T. Weaver
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | | | - Vishhvaan Gopalakrishnan
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Kyle J. Card
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
- Michigan State University, East Lansing, MI, United States of America
| | - Dena Crozier
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Andrew Dhawan
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
- Cleveland Clinic, Division of Neurology, Cleveland, OH, United States of America
| | - Mina N. Dinh
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Emily Dolson
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Nathan Farrokhian
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Masahiro Hitomi
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Emily Ho
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Tanush Jagdish
- Dana Farber Cancer Insitute, Harvard University, Boston, MA, United States of America
| | - Eshan S. King
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | | | | | - Nikhil Krishnan
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Gleb Kuzmin
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Ju Li
- Massachusetts Institute of Technology, Cambridge, MA, United States of America
| | - Jeff Maltas
- University of Michigan, Ann Arbor, MI, United States of America
| | | | - Julia Pelesko
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Jessica A. Scarborough
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Geoff Sedor
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Enze Tian
- Massachusetts Institute of Technology, Cambridge, MA, United States of America
| | - Gary C. An
- University of Vermont Medical Center, Burlington, VT, United States of America
| | - Sean A. Diehl
- University of Vermont Medical Center, Burlington, VT, United States of America
- * E-mail: (SAD); (JGS)
| | - Jacob G. Scott
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
- * E-mail: (SAD); (JGS)
| |
Collapse
|
3
|
Weaver DT, McElvany BD, Gopalakrishnan V, Card KJ, Crozier D, Dhawan A, Dinh MN, Dolson E, Farrokhian N, Hitomi M, Ho E, Jagdish T, King ES, Cadnum JL, Donskey CJ, Krishnan N, Kuzmin G, Li J, Maltas J, Mo J, Pelesko J, Scarborough JA, Sedor G, Tian E, An GC, Diehl SA, Scott JG. UV decontamination of personal protective equipment with idle laboratory biosafety cabinets during the COVID-19 pandemic. PLoS One 2021; 16:e0241734. [PMID: 34310599 DOI: 10.1101/2020.03.25.20043489] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Accepted: 06/19/2021] [Indexed: 05/21/2023] Open
Abstract
Personal protective equipment (PPE) is crucially important to the safety of both patients and medical personnel, particularly in the event of an infectious pandemic. As the incidence of Coronavirus Disease 2019 (COVID-19) increases exponentially in the United States and many parts of the world, healthcare provider demand for these necessities is currently outpacing supply. In the midst of the current pandemic, there has been a concerted effort to identify viable ways to conserve PPE, including decontamination after use. In this study, we outline a procedure by which PPE may be decontaminated using ultraviolet (UV) radiation in biosafety cabinets (BSCs), a common element of many academic, public health, and hospital laboratories. According to the literature, effective decontamination of N95 respirator masks or surgical masks requires UV-C doses of greater than 1 Jcm-2, which was achieved after 4.3 hours per side when placing the N95 at the bottom of the BSCs tested in this study. We then demonstrated complete inactivation of the human coronavirus NL63 on N95 mask material after 15 minutes of UV-C exposure at 61 cm (232 μWcm-2). Our results provide support to healthcare organizations looking for methods to extend their reserves of PPE.
Collapse
Affiliation(s)
- Davis T Weaver
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Benjamin D McElvany
- University of Vermont Medical Center, Burlington, VT, United States of America
| | - Vishhvaan Gopalakrishnan
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Kyle J Card
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
- Michigan State University, East Lansing, MI, United States of America
| | - Dena Crozier
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Andrew Dhawan
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
- Cleveland Clinic, Division of Neurology, Cleveland, OH, United States of America
| | - Mina N Dinh
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Emily Dolson
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Nathan Farrokhian
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Masahiro Hitomi
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Emily Ho
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Tanush Jagdish
- Dana Farber Cancer Insitute, Harvard University, Boston, MA, United States of America
| | - Eshan S King
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | | | | | - Nikhil Krishnan
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Gleb Kuzmin
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Ju Li
- Massachusetts Institute of Technology, Cambridge, MA, United States of America
| | - Jeff Maltas
- University of Michigan, Ann Arbor, MI, United States of America
| | | | - Julia Pelesko
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Jessica A Scarborough
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Geoff Sedor
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| | - Enze Tian
- Massachusetts Institute of Technology, Cambridge, MA, United States of America
| | - Gary C An
- University of Vermont Medical Center, Burlington, VT, United States of America
| | - Sean A Diehl
- University of Vermont Medical Center, Burlington, VT, United States of America
| | - Jacob G Scott
- Cleveland Clinic Lerner Research Institute and Case Western Reserve University School of Medicine, Cleveland, OH, United States of America
| |
Collapse
|
4
|
Graham NR, Whitaker AN, Strother CA, Miles AK, Grier D, McElvany BD, Bruce EA, Poynter ME, Pierce KK, Kirkpatrick BD, Stapleton RD, An G, van den Broek‐Altenburg E, Botten JW, Crothers JW, Diehl SA. Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severity. Clin Transl Immunology 2020; 9:e1189. [PMID: 33072323 PMCID: PMC7541824 DOI: 10.1002/cti2.1189] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Revised: 09/11/2020] [Accepted: 09/11/2020] [Indexed: 01/08/2023] Open
Abstract
OBJECTIVES There is an incomplete understanding of the host humoral immune response to severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2, which underlies COVID-19, during acute infection. Host factors such as age and sex as well as the kinetics and functionality of antibody responses are important factors to consider as vaccine development proceeds. The receptor-binding domain of the CoV spike (RBD-S) protein mediates host cell binding and infection and is a major target for vaccine design to elicit neutralising antibodies. METHODS We assessed serum anti-SARS-CoV-2 RBD-S IgG, IgM and IgA antibodies by a two-step ELISA and neutralising antibodies in a cross-sectional study of hospitalised COVID-19 patients of varying disease severities. Anti-RBD-S IgG levels were also determined in asymptomatic seropositives. RESULTS We found equivalent levels of anti-RBD-S antibodies in male and female patients and no age-related deficiencies even out to 93 years of age. The anti-RBD-S response was evident as little as 6 days after onset of symptoms and for at least 5 weeks after symptom onset. Anti-RBD-S IgG, IgM and IgA responses were simultaneously induced within 10 days after onset, with anti-RBD-S IgG sustained over a 5-week period. Anti-RBD-S antibodies strongly correlated with neutralising activity. Lastly, anti-RBD-S IgG responses were higher in symptomatic COVID-19 patients during acute infection compared with asymptomatic seropositive donors. CONCLUSION Our results suggest that anti-RBD-S IgG reflect functional immune responses to SARS-CoV-2, but do not completely explain age- and sex-related disparities in COVID-19 fatalities.
Collapse
Affiliation(s)
- Nancy R Graham
- Department of Microbiology and Molecular GeneticsLarner College of Medicine, University of VermontBurlingtonVTUSA
- Vaccine Testing CenterLarner College of Medicine, University of VermontBurlingtonVTUSA
| | - Annalis N Whitaker
- Department of Medicine‐ImmunobiologyLarner College of Medicine, University of VermontBurlingtonVTUSA
- Cellular, Molecular, and Biomedical Sciences Graduate ProgramUniversity of VermontBurlingtonVTUSA
- Vermont Center for Immunology and Infectious DiseaseLarner College of Medicine, University of VermontBurlingtonVTUSA
| | - Camilla A Strother
- Department of Microbiology and Molecular GeneticsLarner College of Medicine, University of VermontBurlingtonVTUSA
- Cellular, Molecular, and Biomedical Sciences Graduate ProgramUniversity of VermontBurlingtonVTUSA
| | - Ashley K Miles
- Department of Microbiology and Molecular GeneticsLarner College of Medicine, University of VermontBurlingtonVTUSA
- Vaccine Testing CenterLarner College of Medicine, University of VermontBurlingtonVTUSA
| | - Dore Grier
- Department of Pathology and Laboratory MedicineLarner College of Medicine, University of VermontBurlingtonVTUSA
| | - Benjamin D McElvany
- Department of Microbiology and Molecular GeneticsLarner College of Medicine, University of VermontBurlingtonVTUSA
- Vaccine Testing CenterLarner College of Medicine, University of VermontBurlingtonVTUSA
| | - Emily A Bruce
- Department of Medicine‐ImmunobiologyLarner College of Medicine, University of VermontBurlingtonVTUSA
- Vermont Center for Immunology and Infectious DiseaseLarner College of Medicine, University of VermontBurlingtonVTUSA
- Translational Global Infectious Disease Research CenterUniversity of VermontBurlingtonVTUSA
| | - Matthew E Poynter
- Cellular, Molecular, and Biomedical Sciences Graduate ProgramUniversity of VermontBurlingtonVTUSA
- Vermont Center for Immunology and Infectious DiseaseLarner College of Medicine, University of VermontBurlingtonVTUSA
- Translational Global Infectious Disease Research CenterUniversity of VermontBurlingtonVTUSA
- Vermont Lung CenterLarner College of Medicine, University of VermontBurlingtonVTUSA
- Department of Medicine‐Pulmonary and Critical CareLarner College of Medicine, University of VermontBurlingtonVTUSA
| | - Kristen K Pierce
- Department of Microbiology and Molecular GeneticsLarner College of Medicine, University of VermontBurlingtonVTUSA
- Vaccine Testing CenterLarner College of Medicine, University of VermontBurlingtonVTUSA
- Translational Global Infectious Disease Research CenterUniversity of VermontBurlingtonVTUSA
- Department of Medicine‐Infectious DiseaseLarner College of Medicine University of VermontBurlingtonVTUSA
| | - Beth D Kirkpatrick
- Department of Microbiology and Molecular GeneticsLarner College of Medicine, University of VermontBurlingtonVTUSA
- Vaccine Testing CenterLarner College of Medicine, University of VermontBurlingtonVTUSA
- Vermont Center for Immunology and Infectious DiseaseLarner College of Medicine, University of VermontBurlingtonVTUSA
- Translational Global Infectious Disease Research CenterUniversity of VermontBurlingtonVTUSA
- Department of Medicine‐Infectious DiseaseLarner College of Medicine University of VermontBurlingtonVTUSA
| | - Renee D Stapleton
- Vermont Lung CenterLarner College of Medicine, University of VermontBurlingtonVTUSA
- Department of Medicine‐Pulmonary and Critical CareLarner College of Medicine, University of VermontBurlingtonVTUSA
| | - Gary An
- Translational Global Infectious Disease Research CenterUniversity of VermontBurlingtonVTUSA
- Department of SurgeryLarner College of Medicine, University of VermontBurlingtonVTUSA
| | | | - Jason W Botten
- Department of Microbiology and Molecular GeneticsLarner College of Medicine, University of VermontBurlingtonVTUSA
- Vaccine Testing CenterLarner College of Medicine, University of VermontBurlingtonVTUSA
- Department of Medicine‐ImmunobiologyLarner College of Medicine, University of VermontBurlingtonVTUSA
- Cellular, Molecular, and Biomedical Sciences Graduate ProgramUniversity of VermontBurlingtonVTUSA
- Vermont Center for Immunology and Infectious DiseaseLarner College of Medicine, University of VermontBurlingtonVTUSA
- Translational Global Infectious Disease Research CenterUniversity of VermontBurlingtonVTUSA
| | - Jessica W Crothers
- Vermont Center for Immunology and Infectious DiseaseLarner College of Medicine, University of VermontBurlingtonVTUSA
- Translational Global Infectious Disease Research CenterUniversity of VermontBurlingtonVTUSA
- Department of Medicine‐Infectious DiseaseLarner College of Medicine University of VermontBurlingtonVTUSA
| | - Sean A Diehl
- Department of Microbiology and Molecular GeneticsLarner College of Medicine, University of VermontBurlingtonVTUSA
- Vaccine Testing CenterLarner College of Medicine, University of VermontBurlingtonVTUSA
- Cellular, Molecular, and Biomedical Sciences Graduate ProgramUniversity of VermontBurlingtonVTUSA
- Vermont Center for Immunology and Infectious DiseaseLarner College of Medicine, University of VermontBurlingtonVTUSA
- Translational Global Infectious Disease Research CenterUniversity of VermontBurlingtonVTUSA
| |
Collapse
|
5
|
Graham NR, Whitaker AN, Strother CA, Miles AK, Grier D, McElvany BD, Bruce EA, Poynter ME, Pierce KK, Kirkpatrick BD, Stapleton RD, An G, Botten JW, Crothers JW, Diehl SA. Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age and Biological Sex. medRxiv 2020:2020.07.15.20154443. [PMID: 32743592 PMCID: PMC7386516 DOI: 10.1101/2020.07.15.20154443] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
SARS-CoV-2 is the newly emerged virus responsible for the global COVID-19 pandemic. There is an incomplete understanding of the host humoral immune response to SARS-CoV-2 during acute infection. Host factors such as age and sex as well the kinetics and functionality of antibody responses are important factors to consider as vaccine development proceeds. The receptor-binding domain of the CoV spike (RBD-S) protein is important in host cell recognition and infection and antibodies targeting this domain are often neutralizing. In a cross-sectional study of anti-RBD-S antibodies in COVID-19 patients we found equivalent levels in male and female patients and no age-related deficiencies even out to 93 years of age. The anti-RBD-S response was evident as little as 6 days after onset of symptoms and for at least 5 weeks after symptom onset. Anti-RBD-S IgG, IgM, and IgA responses were simultaneously induced within 10 days after onset, but isotype-specific kinetics differed such that anti-RBD-S IgG was most sustained over a 5-week period. The kinetics and magnitude of neutralizing antibody formation strongly correlated with that seen for anti-RBD-S antibodies. Our results suggest age- and sex- related disparities in COVID-19 fatalities are not explained by anti-RBD-S responses. The multi-isotype anti-RBD-S response induced by live virus infection could serve as a potential marker by which to monitor vaccine-induced responses.
Collapse
|
6
|
Collins MH, Tu HA, Gimblet-Ochieng C, Liou GJA, Jadi RS, Metz SW, Thomas A, McElvany BD, Davidson E, Doranz BJ, Reyes Y, Bowman NM, Becker-Dreps S, Bucardo F, Lazear HM, Diehl SA, de Silva AM. Human antibody response to Zika targets type-specific quaternary structure epitopes. JCI Insight 2019; 4:124588. [PMID: 30996133 DOI: 10.1172/jci.insight.124588] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 03/07/2019] [Indexed: 12/22/2022] Open
Abstract
The recent Zika virus (ZIKV) epidemic in the Americas has revealed rare but serious manifestations of infection. ZIKV has emerged in regions endemic for dengue virus (DENV), a closely related mosquito-borne flavivirus. Cross-reactive antibodies confound studies of ZIKV epidemiology and pathogenesis. The immune responses to ZIKV may be different in people, depending on their DENV immune status. Here, we focus on the human B cell and antibody response to ZIKV as a primary flavivirus infection to define the properties of neutralizing and protective antibodies generated in the absence of preexisting immunity to DENV. The plasma antibody and memory B cell response is highly ZIKV type-specific, and ZIKV-neutralizing antibodies mainly target quaternary structure epitopes on the viral envelope. To map viral epitopes targeted by protective antibodies, we isolated 2 type-specific monoclonal antibodies (mAbs) from a ZIKV case. Both mAbs were strongly neutralizing in vitro and protective in vivo. The mAbs recognize distinct epitopes centered on domains I and II of the envelope protein. We also demonstrate that the epitopes of these mAbs define antigenic regions commonly targeted by plasma antibodies in individuals from endemic and nonendemic regions who have recovered from ZIKV infections.
Collapse
Affiliation(s)
- Matthew H Collins
- Department of Medicine, Emory University, Atlanta, Georgia, USA, and Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur, Georgia, USA.,Department of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - Huy A Tu
- Cellular, Molecular, and Biomedical Sciences Program, University of Vermont, Burlington, Vermont, USA.,Vaccine Testing Center, Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA
| | - Ciara Gimblet-Ochieng
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - Guei-Jiun Alice Liou
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - Ramesh S Jadi
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - Stefan W Metz
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - Ashlie Thomas
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - Benjamin D McElvany
- Vaccine Testing Center, Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA
| | - Edgar Davidson
- Integral Molecular, Inc., Philadelphia, Pennsylvania, USA
| | | | - Yaoska Reyes
- Department of Microbiology, Faculty of Medical Sciences, National Autonomous University of León, Nicaragua
| | - Natalie M Bowman
- Department of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - Sylvia Becker-Dreps
- Departments of Family Medicine and Epidemiology, University of North Carolina at Chapel Hill, Schools of Medicine and Public Health, Chapel Hill, North Carolina, USA
| | - Filemón Bucardo
- Department of Microbiology, Faculty of Medical Sciences, National Autonomous University of León, Nicaragua
| | - Helen M Lazear
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| | - Sean A Diehl
- Cellular, Molecular, and Biomedical Sciences Program, University of Vermont, Burlington, Vermont, USA.,Vaccine Testing Center, Department of Microbiology and Molecular Genetics, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA
| | - Aravinda M de Silva
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
| |
Collapse
|
7
|
Katzelnick LC, Coello Escoto A, McElvany BD, Chávez C, Salje H, Luo W, Rodriguez-Barraquer I, Jarman R, Durbin AP, Diehl SA, Smith DJ, Whitehead SS, Cummings DAT. Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. PLoS Negl Trop Dis 2018; 12:e0006862. [PMID: 30356267 PMCID: PMC6226209 DOI: 10.1371/journal.pntd.0006862] [Citation(s) in RCA: 70] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Revised: 11/09/2018] [Accepted: 09/20/2018] [Indexed: 12/12/2022] Open
Abstract
The gold-standard method for quantifying neutralizing antibody responses to many viruses, including dengue virus (DENV), is the plaque reduction neutralization test (PRNT, also called the immunofocus reduction neutralization test). The PRNT conducted on 96-well plates is high-throughput and requires a smaller volume of antiserum than on 6- or 24-well plates, but manual plaque counting is challenging and existing automated plaque counters are expensive or difficult to optimize. We have developed Viridot (Viridot package), a program for R with a user interface in shiny, that counts viral plaques of a variety of phenotypes, estimates neutralizing antibody titers, and performs other calculations of use to virologists. The Viridot plaque counter includes an automatic parameter identification mode (misses <10 plaques/well for 87% of diverse DENV strains [n = 1521]) and a mode that allows the user to fine-tune the parameters used for counting plaques. We compared standardized manual and Viridot plaque counting methods applied to the same wells by two analyses and found that Viridot plaque counts were as similar to the same analyst's manual count (Lin’s concordance correlation coefficient, ρc = 0.99 [95% confidence interval: 0.99–1.00]) as manual counts between analysts (ρc = 0.99 [95% CI: 0.98–0.99]). The average ratio of neutralizing antibody titers based on manual counted plaques to Viridot counted plaques was 1.05 (95% CI: 0.98–1.14), similar to the average ratio of antibody titers based on manual plaque counts by the two analysts (1.06 [95% CI: 0.84–1.34]). Across diverse DENV and ZIKV strains (n = 14), manual and Viridot plaque counts were mostly consistent (range of ρc = 0.74 to 1.00) and the average ratio of antibody titers based on manual and Viridot counted plaques was close to 1 (0.94 [0.86–1.02]). Thus, Viridot can be used for plaque counting and neutralizing antibody titer estimation of diverse DENV strains and potentially other viruses on 96-well plates as well as for formalization of plaque-counting rules for standardization across experiments and analysts. Although the plaque reduction neutralization test (PRNT) is an important assay for measuring neutralizing antibody responses against many viruses, no free, open-source programs specifically designed for virus plaque counting and neutralizing antibody titer estimation are available. We have developed Viridot, a package for R with a user-interface in shiny, which is designed for use by laboratory-based virologists and researchers with minimal coding experience. The program includes: automatic and user-specification of settings for plaque counting; saving of plaque counting settings; counting of many plates at once; and easy output of plaque counts, plaque sizes, and images with counted plaques circled. Viridot also includes programs to analyze plaque counts, including estimation of: neutralizing antibody titers, pfu/mL of a virus stock, and the dilution factor of virus needed for an experiment. Viridot can be used to standardize plaque-counting methods within and between laboratories, helping researchers formalize an important aspect of the PRNT method that is often subjective. Viridot thus provides laboratory researchers around the world with a free tool to improve the speed and consistency with which the PRNT is conducted, aiding the public health response to emerging viral diseases.
Collapse
Affiliation(s)
- Leah C. Katzelnick
- Department of Biology, University of Florida, Gainesville, FL, United States
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States
- * E-mail:
| | - Ana Coello Escoto
- Department of Biology, University of Florida, Gainesville, FL, United States
| | - Benjamin D. McElvany
- Department of Medicine-Infectious Disease, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, United States
| | - Christian Chávez
- Department of Biology, University of Florida, Gainesville, FL, United States
| | - Henrik Salje
- Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Paris, France
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
| | - Wensheng Luo
- Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
| | - Isabel Rodriguez-Barraquer
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
- School of Medicine, University of California, San Francisco, San Francisco, CA, United States
| | - Richard Jarman
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, United States
| | - Anna P. Durbin
- Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
| | - Sean A. Diehl
- Department of Medicine-Infectious Disease, Vaccine Testing Center, University of Vermont Larner College of Medicine, Burlington, VT, United States
| | - Derek J. Smith
- Department of Zoology, University of Cambridge, Cambridge, United Kingdom
| | - Stephen S. Whitehead
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
| | - Derek A. T. Cummings
- Department of Biology, University of Florida, Gainesville, FL, United States
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
- Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States
| |
Collapse
|
8
|
Diehl SA, Tu H, Nivarthi UK, McElvany BD, Emerling DE, de Silva AM. The human B cell response to infection with dengue virus serotype 2 broadly engages the plasmablast repertoire and maintains a high degree of type-specificity in memory. The Journal of Immunology 2018. [DOI: 10.4049/jimmunol.200.supp.182.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
The complexity of the serological response to the four serotypes of the dengue virus (DENV1-4) is a key factor confounding rational vaccine development for dengue. To refine our understanding of the basis of the humoral response to DENV, we used high-coverage approaches to unravel the early and late B cell response at the clonal level to a single controlled infection with DENV2 in humans. In peripheral blood specimens we identified the peak DENV2-induced early plasmablast response. By analyzing paired immunoglobulin heavy (IGH) and light (IGL) chains derived from peak plasmablasts we found broad evidence of lineage expansion, somatic hypermutation, and variable gene usage. We selected 92 IGH/IGL pairs from expanded lineages and found that 54 (59%) of these monoclonal antibodies (mAb) bound DENV2, five of which also neutralized virus. In these same subjects we assessed the memory B cell (MBC) repertoire at six months post infection by screening IgG from MBCs immortalized by genetic reprogramming to a germinal center-like state. Compared to the early plasmablast response, we found a drastic reduction in the DENV-specific population in the memory phase of the B cell response. There was a unexpectedly high degree of DENV2 type-specificity in the convalescent MBC pool, though heterotypic clones were also observed. MBC-derived mAbs mainly reacted to epitopes present on whole virions. Our results suggest that controlled DENV2 infection elicits a broad and complex early B cell response to DENV that contracts to yield a DENV-specific MBC compartment. These results provide insights into the basis for long-term serotype-specific humoral immunity and provide additional metrics by which to assess DENV vaccines.
Collapse
|
9
|
Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Opert K, Jarvis AP, Sabundayo BP, McElvany BD, Sendra EA, Larsson CJ, Jo M, Lovchik JM, Luke CJ, Walsh MC, Fraser EA, Subbarao K, Whitehead SS. A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. J Infect Dis 2016; 214:832-5. [PMID: 26908742 PMCID: PMC4996143 DOI: 10.1093/infdis/jiw067] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Accepted: 01/11/2016] [Indexed: 01/08/2023] Open
Abstract
UNLABELLED The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary. CLINICAL TRIALS REGISTRATION NCT01782300.
Collapse
Affiliation(s)
- Anna P Durbin
- Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore
| | - Beth D Kirkpatrick
- Vaccine Testing Center, University of Vermont College of Medicine, Burlington
| | - Kristen K Pierce
- Vaccine Testing Center, University of Vermont College of Medicine, Burlington
| | - Marya P Carmolli
- Vaccine Testing Center, University of Vermont College of Medicine, Burlington
| | - Cecilia M Tibery
- Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore
| | - Palmtama L Grier
- Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore
| | - Noreen Hynes
- Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore
| | - Kari Opert
- Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore
| | - Adrienne P Jarvis
- Vaccine Testing Center, University of Vermont College of Medicine, Burlington
| | - Beulah P Sabundayo
- Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore
| | - Benjamin D McElvany
- Vaccine Testing Center, University of Vermont College of Medicine, Burlington
| | - Eli A Sendra
- Vaccine Testing Center, University of Vermont College of Medicine, Burlington
| | - Catherine J Larsson
- Vaccine Testing Center, University of Vermont College of Medicine, Burlington
| | - Matthew Jo
- Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore
| | - Janece M Lovchik
- Center for Immunization Research, Johns Hopkins University School of Public Health, Baltimore
| | - Catherine J Luke
- Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland
| | - Mary C Walsh
- Vaccine Testing Center, University of Vermont College of Medicine, Burlington
| | - Ellen A Fraser
- Vaccine Testing Center, University of Vermont College of Medicine, Burlington
| | - Kanta Subbarao
- Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland
| | - Stephen S Whitehead
- Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland
| |
Collapse
|